Delivery Order SPE2DB20D1100-SPE2DB25FE0NE
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,352.44 for 100-unit vials of Xeomin, a botulinum toxin injection used primarily for treating muscle spasticity and other neurological conditions. This non-competitive, firm fixed-price delivery order was awarded on July 22, 2025, with an ultimate completion date of August 12, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $27,937 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a non-competitive, direct fulfillment order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $3,352.44 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of XEOMIN, a botulinum toxin-based therapeutic product commonly used for medical and cosmetic purposes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency (DLA) awarded a $30,878.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside contract, issued on September 17, 2025, with completion targeted for October 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The IDC, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $3,039.40 to AmerisourceBergen Drug Corp for 50-unit vials of XEOMIN, a botulinum toxin product used for medical and therapeutic purposes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $26,819.52 delivery order to AmerisourceBergen Drug Corp for 200 unit vials of XEOMIN, a botulinum toxin product used for therapeutic and cosmetic medical applications. Issued on August 19, 2025, with an ultimate completion date of September 10, 2025, this firm fixed-price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for 100-unit vials of XEOMIN, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, valued at $8,381.10, is scheduled for completion by September 11, 2025, and will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the company's proven...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0NEDelivery Order
The Defense Logistics Agency awarded a $33,524.40 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of XEOMIN, a botulinum toxin injection used primarily for treating muscle spasticity and dystonia in military and veteran healthcare populations. This non-set-aside contract, awarded on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, particularly for defense healthcare systems. As the primary vendor under the comprehensive SPE2DX IDC, AmerisourceBergen supplies a broad spectrum of specialty medications, brand-name and generic pharmaceuticals, and medical supplies to support military healthcare operations globally. The company's federal contract portfolio demonstrates consistent capability to fulfill competitive procurements across diverse therapeutic domains and order values, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities through flexible and scalable contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.5k | 9/18/25 |